




FN MOTOL



**KARDIOLOGICKÁ
KLINIKA**




2. LF UK

Ke správné diagnóze napříč kardiomyopatiemi

Veronika Gašpárková

Kardiologická klinika 2. LF UK a FN Motol | Praha


ČASS 10.10.2025






11/2011



TTE









**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL

Sportovní srdce x incipientní HCM ?




terminace AVNRT




04/2012

Kontrola po 5 letech...


EKG




TTE 2020




HCM x ARVC ?




MRI






**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL



**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL

MRI (LGE)



MRI (LGE)

ARVC?





Table 1 Comparison of original and revised task force criteria

Original task force criteria	Revised task force criteria
I. Global or regional dysfunction and structural alterations*	
<u>Major</u>	
<ul style="list-style-type: none"> • Severe dilatation and reduction of RV ejection fraction with no (or only mild) LV impairment • Localized RV aneurysms (akinetic or dyskinesic areas with diastolic bulging) • Severe segmental dilatation of the RV 	<p>By 2D echo:</p> <ul style="list-style-type: none"> • Regional RV akinesia, dyskinesia, or aneurysm • and 1 of the following (end diastole): <ul style="list-style-type: none"> — PLAX RVOT ≥ 32 mm (corrected for body size [PLAX/BSA] ≥ 19 mm/m²) — PSAX RVOT ≥ 36 mm (corrected for body size [PSAX/BSA] ≥ 21 mm/m²) — or fractional area change $\leq 33\%$ <p>By MRI:</p> <ul style="list-style-type: none"> • <u>Regional RV akinesia or dyskinesia or dyssynchronous RV contraction</u> • and 1 of the following: <ul style="list-style-type: none"> — <u>Ratio of RV end-diastolic volume to BSA ≥ 110 mL/m² (male) or ≥ 100 mL/m² (female)</u> — or RV ejection fraction $\leq 40\%$ <p>By RV angiography:</p> <ul style="list-style-type: none"> • Regional RV akinesia, dyskinesia, or aneurysm
<u>Minor</u>	
<ul style="list-style-type: none"> • Mild global RV dilatation and/or ejection fraction reduction with normal LV • Mild segmental dilatation of the RV • Regional RV hypokinesia 	<p>By 2D echo:</p> <ul style="list-style-type: none"> • Regional RV akinesia or dyskinesia • and 1 of the following (end diastole): <ul style="list-style-type: none"> — PLAX RVOT ≥ 29 to < 32 mm (corrected for body size [PLAX/BSA] ≥ 16 to < 19 mm/m²) — PSAX RVOT ≥ 32 to < 36 mm (corrected for body size [PSAX/BSA] ≥ 18 to < 21 mm/m²) — or fractional area change $> 33\%$ to $\leq 40\%$ <p>By MRI:</p> <ul style="list-style-type: none"> • Regional RV akinesia or dyskinesia or dyssynchronous RV contraction • and 1 of the following: <ul style="list-style-type: none"> — <u>Ratio of RV end-diastolic volume to BSA ≥ 100 to < 110 mL/m² (male) or ≥ 90 to < 100 mL/m² (female)</u> — <u>or RV ejection fraction $> 40\%$ to $\leq 45\%$</u>

MRI






Table I Continued

Original task force criteria	Revised task force criteria
IV. Depolarization/conduction abnormalities	
Major	
<ul style="list-style-type: none">Epsilon waves or localized prolongation (> 110 ms) of the QRS complex in right precordial leads (V₁ to V₃)	<ul style="list-style-type: none">Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V₁ to V₃)
Minor	
<ul style="list-style-type: none">Late potentials (SAECG)	<ul style="list-style-type: none">Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS duration of ≥ 110 ms on the standard ECGFiltered QRS duration (fQRS) ≥ 114 msDuration of terminal QRS < 40 μV (low-amplitude signal duration) ≥ 38 msRoot-mean-square voltage of terminal 40 ms ≤ 20 μV

Molekulárně genetické vyšetření (NGS):


DSC2 c.1263+2T>G - **patogenní**

DCS2 c.595C>T p.(Arg199Cys) - VUS

Minor	<ul style="list-style-type: none">Identification of a pathogenic mutation: categorized as associated or probably associated with ARVC/D in the patient under evaluation
<ul style="list-style-type: none">Family history of premature sudden death (<35 years of age) due to suspected ARVC/DFamilial history (clinical diagnosis based on present criteria)	<ul style="list-style-type: none">History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteriaPremature sudden death (<35 years of age) due to suspected ARVC/D in a first-degree relativeARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative



2020




Kontrola po 5 letech...




I 53 230 - V_F 228 V_F 235 [vs] - V₈₀ V₈₅ V₁₀ V₈₈ V₉₀ V₉₃ V₉₀ V₈₈ V₈₅ V₈₈ V₉₀ V₈₈ V₉₀

Chrg 41J Shk



V₈₅ V₈₈ V₈₈ V₈₈ V₈₈ V₈₈ V₈₈ V₈₃ V₈₈

EKG



25mm/s 10mm/mV 150Hz 10.1.2 12SL 243 CID: 4

EID: 13 EDT: ORDER:


09/2025



**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL

TTE 2025







**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL





**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL



Mohla být dg. časněji?







**KARDIOLOGICKÁ
KLINIKA**
2. LF UK a FN MOTOL


Take home message

- Multimodální přístup
- Pečlivá OA, RA a screening příbuzných
 - EKG, holter EKG
 - TTE a/nebo MRI
 - genetické vyšetření
- Dlouhodobý pravidelné sledování
- Restrikce intenzivní sportovní aktivity
 - riziko progrese fenotypu
- Prevence arytmiické SCD implantací ICD
 - sekundární prevence
 - primární prevence

Recommendations	Class ^a	Level ^b
Secondary prevention		
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in patients with ARVC who have survived a cardiac arrest or have recovered from a ventricular arrhythmia causing haemodynamic instability. ^{939,943,944,948,949}	I	A
An ICD should be considered in ARVC patients who have suffered a haemodynamically tolerated VT. ^{522,939,943-945,948-950}	IIa	B
Primary prevention		
High-risk features ^c should be considered to aid individualized decision-making for ICD implantation in patients with ARVC. ^{538,939}	IIa	B
The updated 2019 ARVC risk calculator should be considered to aid individualized decision-making for ICD implantation in patients with ARVC. ^{d,524,526,536-539}	IIa	B



FN MOTOL



**KARDIOLOGICKÁ
KLINIKA**



2. LF UK

Děkuji za pozornost!

Veronika Gašpárková

Kardiologická klinika 2. LF UK a FN Motol | Praha

ČASS 10.10.2025